Showing 5381-5390 of 6661 results for "".
- Sciton Rolls Out BBLINK Goggles for Improved Eye Protectionhttps://practicaldermatology.com/news/sciton-rolls-out-bblink-goggles-for-improved-eye-protection/2460903/Sciton Inc. is launching BBLINK Goggles. These smart glasses physically blink for the user to block out strain inducing light flashes, leading to improved treatment visibility and a more pleasant experience for the practitioner. BBLINK Goggles feature proprietary technol
- New Melanoma Staging System May Better Predict Prognosishttps://practicaldermatology.com/news/new-melanoma-staging-system-may-better-predict-prognosis/2460901/A new system for classifying melanoma when the disease has spread to the lymph nodes may offer a better tool for predicting patients' outcomes and determining their treatment needs, according to research in
- Sun Pharma, Cassiopea Move Ahead with Winlevi Agreementhttps://practicaldermatology.com/news/sun-pharma-cassiopea-move-ahead-with-winlevi-agreement/2460899/Sun Pharma and Cassiopea SpA announced the expiration of the applicable waiting period under the US Hart-Scott-Rodino Antitrust Improvements Act of 1976 (HSR Act) in connection with the exclusive License and Supply Agreements signed by both companies for Winlevi (clascoterone cream 1%).
- Experts Call for Greater Attention to Persistent Redness of Rosaceahttps://practicaldermatology.com/news/experts-call-for-greater-attention-to-persistent-redness-of-rosacea/2460896/Dermatologists should place greater emphasis on persistent facial erythema of rosacea, a panel of experts concludes. Their recommendations, based on a National Rosacea Society (NRS) roundtable conversation, appear in the <
- First Patient Dosed in Kinnate's Phase 1 trial of KIN-2787 in Patients with BRAF Mutation-Positive Solid Tumorshttps://practicaldermatology.com/news/first-patient-dosed-in-kinnates-phase-1-trial-of-kin-2787-in-patients-with-braf-mutation-positive-solid-tumors/2460894/The first patient has commenced treatment in Kinnate Biopharma Inc.’s Phase 1 KN-8701 trial of its lead RAF product candidate, KIN-2787, a pan-RAF inhibitor being developed for the treatment of patients with melanoma, lung cancer, and other solid tumors. While three kina
- FDA Approves Amendment to Avita's Vitiligo Trial Designhttps://practicaldermatology.com/news/fda-approves-amendment-to-avitas-vitiligo-trial-design/2460893/Avita Medical, Inc. will move forward with an amended pivotal clinical trial evaluating the safety and effectiveness of the RECELL® System for the repigmentation of stable vitiligo lesions to a streamlined single-arm trial design, now that the FDA has approved the trial modification. The
- UV Index Today is Helping to Reduce Skin Cancer Rates with Web Technologyhttps://practicaldermatology.com/news/uv-index-today-is-helping-to-reduce-skin-cancer-rates-with-web-technology/2460891/UV Index Today launched their free UV forecasting service to help people track the sun’s ultraviolet radiation
- New Survey: Americans Have Missed Out on Dating, Parties, School And Work Because of Acnehttps://practicaldermatology.com/news/new-survey-americans-have-missed-out-on-dating-parties-school-and-work-because-of-acne/2460889/Americans missed out on dating, school and hanging out with friends because of acne during the past year, according to a new survey by University Medical, the manufacturer of the Acne Wipeout skincare system. After more than a year of looking at themselves on screens and hiding behind s
- Patricia Treadwell, MD Assumes Presidency of Society for Pediatric Dermatologyhttps://practicaldermatology.com/news/patricia-treadwell-md-assumes-presidency-of-society-fir-pediatric-dermatology/2460888/Patricia Treadwell, MD is new President of the Society for Pediatric Dermatology (SPD). She assumed the role and the society and seated its new 2021-2022 Executive Committee members during the 46th Annual Conference last month. Dr. Treadwell is jo
- Bausch Health Plans IPO of Solta Medical Aesthetics Unithttps://practicaldermatology.com/news/bausch-health-plans-ipo-of-solta-medical-aesthetics-unit/2460880/Bausch Health Companies Inc. is planning to pursue an initial public offering (IPO) of its Solta Medical business. Solta’s portfolio includes the Thermage RF systems, Fraxel laser, Clear + Brilliant laser and VASER ultrasonic systems. The timing of the anticipated IPO, w